1DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long - term complication in insulindependent diabetes mellitus. THe New Engl J Med 1993 ;329(14) :977 - 986.
2DCCT Research Group. The Diabetes Control and Complication Trial(DCCT), design and methodologic considerations for the faasibility phase. Diabetes 1986 ; 35 (50 : 530 - 545.
4Wilde MI and McTavish D, Insulin Lispro: A reveiew of its pharmacological properties and therapeutic use tin the management of diabetes mellitus. Drogs 1997;54(4) :597-614.
5Chance RE, Llewelyn J, Heinemann L, et al. Insul; in Lispro:A new rapid - acting insulin analog. Drugs of Today 1998 ; 34 (Suppl. C) : 1 - 50.
6Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart(B28 asp- insulin) : a fast- acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, Diabetes Care 1999 ; 22(9) : 1501 - 1506.
7Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous in sulin infusion. Diabetes Care 2002; 25 (3) :439 - 444.
8Lahtela JT, Knir M, Paul R, et al. Severe antibody - mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 1997;20(1):71-73.
9Holleman F, Schmitt H, Rottiers Re, t al. Reduced frequency of svevere hypogycemia and coma in well- controlled ID DM patients treated with insulin lispro. Diabetes Care 1997 ;20(12):1827 - 1832.
10Kramer W. New approaches to the treatment of diabetes. Exp Clin Endocrinol Diabetes 1999 ; 107 ( Suppl. 2) : S52-S61.
